Impact BioMedical (IBO) vs Metagenomi Therapeutics (MGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Impact BioMedical (IBO) has outperformed Metagenomi Therapeutics (MGX) over the past year, losing 42.7% versus a loss of 68.9%. Metagenomi Therapeutics is the larger company by market cap ($37.5 million vs $35.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IBO | MGX |
|---|---|---|
| Share price | $4.11 | $0.9932 |
| Market cap | $35.11M | $37.52M |
| 1-day change | -8.26% | +0.86% |
| YTD return | -29.92% | -38.69% |
| 1-year return | -42.73% | -68.87% |
| P/E ratio (TTM) | 0.37 | — |
| EPS (TTM) | $11.11 | $-2.49 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.51 | $3.95 |
| 52-week low | $4.10 | $0.96 |
| Distance from 52-week high | -60.88% | -74.86% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +604.79% |
| Average volume | 11.61K | 158.27K |
| Shares outstanding | 8.54M | 37.78M |
| Employees | 2 | 113 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IBO has outperformed MGX by 26.1 percentage points over the past year.
About Impact BioMedical
IBO stock →Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States.
Healthcare · Biotechnology · 2 employees
About Metagenomi Therapeutics
MGX stock →Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States.
Healthcare · Biotechnology · 113 employees
IBO vs MGX FAQ
Which is bigger, Impact BioMedical or Metagenomi Therapeutics?
Metagenomi Therapeutics (MGX) is larger, with a market capitalization of $37.52M compared with $35.11M for Impact BioMedical (IBO).
Which stock has performed better over the past year, IBO or MGX?
IBO returned -42.73% over the past 12 months, compared with -68.87% for MGX (price return, excluding dividends). Past performance does not predict future results.
Are Impact BioMedical and Metagenomi Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.